Clinical review report: Bictegravir/Emtricitabine/Tenofovir alafenamide (B/FTC/TAF) (Biktarvy) (Gilead Sciences Canada, Inc.) indication : a complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance to the individual components of Biktarvy
The objective of this systematic review was to evaluate the efficacy and safety of the fixed-dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) 50 mg/200 mg/25 mg, once daily, as a treatment for HIV type 1 (HIV-1) infection in adults with no known substitution associa...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, October 2018
|
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this systematic review was to evaluate the efficacy and safety of the fixed-dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) 50 mg/200 mg/25 mg, once daily, as a treatment for HIV type 1 (HIV-1) infection in adults with no known substitution associated with resistance to the individual components of B/FTC/TAF. Of which, B is an integrase strand transfer inhibitor, and both emtricitabine (FTC) and tenofovir alafenamide (TAF) are nucleoside reverse transcriptase inhibitors |
---|---|
Item Description: | "Version: Final with redactions." |
Physical Description: | 1 PDF file (90 pages) |